ZEAL

Zealand Pharma A/S. - ADR

$16.88

chg

0.00 (0.00%)

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

9.93

52 wk hi

34.3

Cash

$167.1M

Burn Rate (Qtr)

$47.2M

Mkt Cap

$785.4m

Avg Volume

3,950

*cash/burn updated:

Q1 '22

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Dasiglucagon

Congenital Hyperinsulinism

NDA

Submission

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Glepaglutide

Short bowel syndrome

Phase 3

Interim Update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Dasiglucagon

Type 1 diabetes

Phase 3

Initiation

Exp Date

A free account is required to see the catalyst dates, notes, and more!

BI 456906 (GLP-1/glucagon dual agonist)

Obesity, Non-alcoholic steatohepatitis

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Dasiglucagon

Type 1 diabetes

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

ZEAL

BPIQ_Logo_RGB-01.jpg

Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs.

Recent Posts

See what the community is saying - click to see full post.